Promising GVHD prevention trial halted early – too few patients to draw conclusions
NCT ID NCT06271616
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tested whether the drug ibrutinib could prevent chronic graft-versus-host disease (GVHD) in adults who had received a donor stem cell transplant. Only 2 people enrolled before the study was terminated early. Because of the very small number of participants, no reliable conclusions can be drawn about whether ibrutinib helps prevent GVHD.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ibrutinib
What this could lead to
If this approach had worked, it could have pointed toward a way to prevent chronic GVHD after stem cell transplants.
What could go wrong
The trial was terminated early with only 2 participants, so we have very little data. It is unclear if ibrutinib is effective or safe for this use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC AND LYMPHATIC SYSTEM NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980, United States